XHKG
2190
Market cap812mUSD
Oct 09, Last price
20.50HKD
1D
-0.10%
1Q
6.38%
IPO
-63.29%
Name
Zylox-Tonbridge Medical Technology Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Zylox-Tonbridge Medical Technology Co., Ltd. is a global medical device firm specializing in neurovascular and peripheral vascular interventional technologies. Their comprehensive product line for treating ischemic stroke includes the ThromBite Clot Retriever, designed to extract clots from major brain vessels, as well as aspiration and balloon guiding catheters. For peripheral vascular conditions, they offer the ZENFLEX Pro Drug-eluting Stent System for managing complex and recurring symptomatic lesions, the self-expanding ZENFlex Peripheral Stent System for deployment in the iliac, superficial femoral, and proximal popliteal arteries, and drug-coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheters for treating arterial stenoses or blockages in these same regions. Their neurovascular offerings further extend to Ton-Bridge extra soft coils, utilized for the endovascular embolization of intracranial aneurysms and other cerebral vascular malformations like arteriovenous malformations (AVMs) and fistulae. Supporting these are a range of microcatheters (for coiling or selective agent delivery), distal access and intracranial PTA balloon catheters, vascular snares, and IVC filter snare retrieval kits. Established in 2012, Zylox-Tonbridge Medical Technology Co., Ltd. maintains its headquarters in Zhejiang, People's Republic of China.
Key people
Zheng Li
Senior Vice President, Executive Director · since 2021
Ning Pan
Senior Vice President · since 2019
Yang Xie
Senior Vice President, Executive Director · since 2021
Jonathon Zhong Zhao
Executive Chairman of the Board, Chief Executive Officer, Founder · since 2021
Kai Cheong Cheung
Joint Company Secretary
Quanwei Yuan
Chief Financial Officer, Joint Company Secretary · since 2021
Dongfang Li
Non-Executive Director · since 2022
Dasong Wang
Non-Executive Director · since 2021
Jian Ji
Non-Executive Independent Director · since 2021
Yun Qiu
Non-Executive Independent Director · since 2021
Qian Xiang
Non-Executive Independent Director
Legal address
1st and 2nd Floors, Building 1, No. 18 Keji Avenue
Yuhang District
Hangzhou, ZJ 311121
CN
Yuhang District
Hangzhou, ZJ 311121
CN
Headquarters
No. 270, Shuyun Road, Cangqian Street
Yuhang District
Hangzhou, ZJ 311121
CN
Yuhang District
Hangzhou, ZJ 311121
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||